[ad_1]
According to the World Health Organization, schizophrenia “is a serious mental disorder affecting more than 21 million people worldwide.” The same institution explains that “it is curable” and that “pharmacotherapy and psychosocial support are effective”. The most recent references for Spain estimate the prevalence of schizophrenia in a 1 percent of the adult population.
With the aim of knowing the latest data on the treatment of schizophrenia, Angelini Pharma Spain organized a digital meeting that allowed to present the latest clinical data of Lurasidone and to share the experience of real use of the product in patients with severe mental pathology. .
Well tolerated
According to Leslie Citrome of New York Medical College (Valhalla, New York), in her experience with lurasidone over the past 10 years, it is “an effective drug that is also effective in real life. It reduces the symptoms of schizophrenia and at the same time is very well tolerated by patients with schizophrenia. Citrome explained that he usually prescribes it “in its highest dose, 160 mg / day, particularly in those patients who do not respond as well as would be expected at 80 mg / day”. “There is evidence from clinical trials to support this choice” and furthermore, the side effects are reduced: “I know I won’t find weight gain often, at least compared to my experience with other second generation antipsychotics“, Insert.
Good cognitive profile
For his part, Philip D. Harvey, expert in neurocognition and functional recovery, pointed out that “Lurasidone is a non-sedative compound that does not have anticholinergic properties. Consequently, compared to other atypical antipsychotics, it has a very beneficial cognitive profile“.” This cognitive profile is likely to translate into better daily functioning, which is really the essence of efficacy in treating people with schizophrenia. “On the other hand,” the lack of weight gain associated with taking of Lurasidone has other important implications, as the development of type 2 diabetes is damaging to the brain and is associated with the cognitive changes themselves. ”
Maximize the benefits of change
To get the best response in patients, Eduard Vieta, professor of psychiatry at the University of Barcelona and head of the psychiatry department at the Hospital Clínic, stressed that “Lurasidone is an option in the treatment of schizophrenia that also provides benefits in affective and cognitive symptoms. Due to its tolerability profile, it is an excellent drug for transferring some patients from other treatments with questionable tolerability to lurasidone, an effective treatment that has better tolerability while preserving the efficacy of the initial drug “. To achieve the best efficiency,”It’s important take into account the previous drug profile and the lurasidone profile to maximize the benefits of the switching process“, He says.
All these data on the use of lurasidone in patients with schizophrenia, from different studies, were presented in the Web seminar organized by Angelini Pharma Spain. Interested professionals can retrieve the content at the following link: https://globalmeet.webcasts.com/starthere.jsp?ei=1378874&tp_key=7fa378c63e
Olga Insua, Country Manager of Angelini Pharma Spain explains that “We have a firm commitment to the environment and that is why we believe that the patient, together with the healthcare professional, should be at the center of our business with the common goal of improving their quality of life. Furthermore, we are always alongside professionals and for this reason we want to provide them with access to scientific information and the most up-to-date knowledge to help them develop their business ”, he concludes.
Source link
